Terje R. Pedersen

61.3k citations

171 papers · 25.2k indexed · 17 hit papers · h-index 68

Surgery top 0.02%
Cardiology and Cardiovascular Medicine top 0.1%
Endocrinology, Diabetes and Metabolism top 0.05%
Economics and Econometrics top 0.05%
Cancer Research top 0.2%

Co-authors: Anders Olsson John Kjekshus Kalevi Pyörälà Ole Færgeman Ingar Holme Robert P. Giugliano Marc S. Sabatine Anthony Keech
Topics: Lipoproteins and Cardiovascular Health (123 papers)Health Systems, Economic Evaluations, Quality of Life (47 papers)Pharmaceutical Economics and Policy (30 papers)
Cited by: Endocrinology, Diabetes and Metabolism Surgery Cardiology and Cardiovascular Medicine
Journals: New England Journal of Medicine The Lancet JAMA
Partner nations: Norway United States United Kingdom

In The Last Decade

Terje R. Pedersen

171 papers receiving 24.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

2016 2.1k citations Terje R. Pedersen et al. profile →
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

2004 1.9k citations Terje R. Pedersen profile →
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

2016 1.3k citations Terje R. Pedersen et al. profile →
Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1997 1.2k citations Kalevi Pyörälà, Terje R. Pedersen et al. profile →
High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction<SUBTITLE>The IDEAL Study: A Randomized Controlled Trial</SUBTITLE>

2005 1.1k citations Terje R. Pedersen profile →
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis

2008 1.1k citations Anne B. Rossebø, Terje R. Pedersen et al. profile →
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials

2015 1.0k citations Terje R. Pedersen et al. The Lancet profile →
Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes

2004 971 citations Terje R. Pedersen et al. profile →
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

2003 660 citations Hallvard Holdaas, Bengt Fellström et al. The Lancet profile →
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk

2019 585 citations Michelle L. O’Donoghue, Robert P. Giugliano et al. Circulation profile →
Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins

2012 577 citations Terje R. Pedersen, John C. LaRosa et al. profile →
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease

2017 491 citations Marc P. Bonaca, Patrice Nault et al. Circulation profile →
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

2017 469 citations Robert P. Giugliano, Terje R. Pedersen et al. The Lancet profile →
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

2017 400 citations Marc S. Sabatine, Lawrence A. Leiter et al. profile →
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials

2018 365 citations Terje R. Pedersen, Anders Olsson et al. The Lancet profile →
Cognitive Function in a Randomized Trial of Evolocumab

2017 329 citations Robert P. Giugliano, François Mach et al. profile →
Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol

2014 285 citations Terje R. Pedersen et al. profile →

Peers

Countries citing papers authored by Terje R. Pedersen

Since Specialization

Citations

This map shows the geographic impact of Terje R. Pedersen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terje R. Pedersen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terje R. Pedersen more than expected).

Fields of papers citing papers by Terje R. Pedersen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Terje R. Pedersen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terje R. Pedersen. The network helps show where Terje R. Pedersen may publish in the future.

Co-authorship network of co-authors of Terje R. Pedersen

This figure shows the co-authorship network connecting the top 25 collaborators of Terje R. Pedersen. A scholar is included among the top collaborators of Terje R. Pedersen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Terje R. Pedersen. Terje R. Pedersen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism 2020 ·Circulation ·Nicholas Marston,Yared Gurmu,Giorgio Melloni,Marc P. Bonaca,Bariş Gencer,Peter S. Sever,Terje R. Pedersen,Anthony Keech,Carolina Roselli,Steven A. Lubitz,Patrick T. Ellinor,Michelle L. O’Donoghue,Robert P. Giugliano,Christian T. Ruff,Marc S. Sabatine	65
2	Abstract 13871: Evolocumab and Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: Analysis From FOURIER 2019 ·Circulation ·Bariş Gencer,François Mach,Sabina A. Murphy,Gaetano Maria De Ferrari,Kurt Huber,Basil S. Lewis,Jorge Ferreira,Christopher E. Kurtz,Huei Wang,Narimon Honarpour,Anthony Keech,Peter S. Sever,Terje R. Pedersen,Marc S. Sabatine,Robert P. Giugliano	1
3	Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial 2019 ·Journal of the American College of Cardiology ·David M. Charytan,Marc S. Sabatine,Terje R. Pedersen,(unknown),Jeong‐Gun Park,Armando Lira Pineda,Scott M. Wasserman,Prakash Deedwania,Anders Olsson,Peter Sever,Anthony Keech,Robert P. Giugliano	121
4	Inflammatory and Cholesterol Risk in the FOURIER Trial 2018 ·Circulation ·Erin A. Bohula,Robert P. Giugliano,Lawrence A. Leiter,Subodh Verma,Jeong‐Gun Park,Peter Sever,Armando Lira Pineda,Narimon Honarpour,Huei Wang,Sabina A. Murphy,Anthony Keech,Terje R. Pedersen,Marc S. Sabatine	193
5	Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Diseasebreakdown → 2017 ·Circulation ·Marc P. Bonaca,Patrice Nault,Robert P. Giugliano,Anthony Keech,Armando Lira Pineda,Estella Kanevsky,Julia Kuder,Sabina A. Murphy,J. Wouter Jukema,Basil S. Lewis,Lâle Tokgözoğlu,Ransi Somaratne,Peter Sever,Terje R. Pedersen,Marc S. Sabatine	491
6	Abstract 15100: Reduction in Total Cardiovascular Events With the PCSK9 Inhibitor Evolocumab in Patients With Cardiovascular Disease in the FOURIER Trial 2017 ·Circulation ·Sabina A. Murphy,Terje R. Pedersen,Zbigniew Gaciong,R Češka,М. В. Ежов,Derek Connolly,(unknown),J. Wouter Jukema,(unknown),Matti J. Tikkanen,Canqing Yu,Stephen D. Wiviott,Christopher E. Kurtz,Narimon Honarpour,Robert P. Giugliano,Anthony Keech,Peter Sever,Marc S. Sabatine	3
7	A Missense Variant in PLEC Increases Risk of Atrial Fibrillation 2017 ·Journal of the American College of Cardiology ·Rósa B. Þórólfsdóttir,Garðar Sveinbjörnsson,Patrick Sulem,Anna Helgadóttir,Sólveig Grétarsdóttir,Stefania Benónísdóttir,Audur Magnusdottir,Olafur B. Davidsson,Sridharan Rajamani,Dan M. Roden,Dawood Darbar,Terje R. Pedersen,Marc S. Sabatine,Ingileif Jónsdóttir,Davíð O. Arnar,Unnur Þorsteinsdóttir,Daníel F. Guðbjartsson,Hilma Hólm,Kāri Stefánsson	56
8	Effect Modifications of Lipid-Lowering Therapy on Progression of Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study) 2017 ·The American Journal of Cardiology ·Anders M. Greve,Casper N. Bang,Kurt Boman,Kenneth Egstrup,Julie Lyng Forman,Y. Antero Kesäniemi,Simon Ray,Terje R. Pedersen,Patricia J.M. Best,Nalini M. Rajamannan,Kristian Wachtell	21
9	Incidence of Cancer and Mortality in Patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Trial 2014 ·The American Journal of Cardiology ·Anders Green,Dena Rosen Ramey,Martha Emneus,Maria Iachina,Knut Stavem,Kristian Bolin,Richard McNally,Michael Busch-Sørensen,Ronnie Willenheimer,Kenneth Egstrup,Y. Antero Kesäniemi,Simon Ray,Nermine O. Basta,(unknown),Terje R. Pedersen	20
10	Impact of Obesity and Nonobesity on Grading the Severity of Aortic Valve Stenosis 2014 ·The American Journal of Cardiology ·(unknown),Eva Gerdts,Dana Cramariuc,Edda Bahlmann,Nikolaus Jander,Christa Gohlke-Bärwolf,Terje R. Pedersen,Mai Tone Lønnebakken	10
11	Abstract 18079: Among CHD Patients in the IDEAL Study, Those with Elevated Levels of Alanine Aminotransferase at Baseline Had a Lower Rate of Major Coronary Events 2011 ·Circulation ·Matti J. Tikkanen,Rana Fayyad,Rachel Laskey,Ingar Holme,Ole Færgeman,Anders Olsson,Christina Lindahl,John J.P. Kastelein,Mogens Lytken Larsen,Terje R. Pedersen,(unknown)	1
12	Risk factors for unexpected sudden death in patients with non-symptomatic aortic stenosis (the SEAS study) 2010 ·Lund University Publications (Lund University) ·Anne B. Rossebø,Christa Gohlke-Bärwolf,Kurt Boman,Joseph B. Chambers,Eva Gerdts,Ingar Holme,(unknown),Kristian Wachtell,Ronnie Willenheimer,Terje R. Pedersen	2
13	Total Cardiovascular Disease Burden: Comparing Intensive With Moderate Statin Therapy 2009 ·Journal of the American College of Cardiology ·Matti J. Tikkanen,Michael Szarek,Rana Fayyad,Ingar Holme,Nilo B. Cater,Ole Færgeman,John J.P. Kastelein,Anders Olsson,Mogens Lytken Larsen,Christina Lindahl,Terje R. Pedersen	44
14	Effects of a low glycemic load diet versus a low-fat diet in subjects with and without the metabolic syndrome 2009 ·Nutrition Metabolism and Cardiovascular Diseases ·Tor Ole Klemsdal,Ingar Holme,(unknown),Terje R. Pedersen,Serena Tonstad	54
15	Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL) 2008 ·Annals of Medicine ·Ingar Holme,Nilo B. Cater,Ole Færgeman,John J.P. Kastelein,Anders Olsson,Matti J. Tikkanen,Mogens Lytken Larsen,Christina Lindahl,Terje R. Pedersen,(unknown)	44
16	Abstract 3357: Superiority of ApoB/ApoA1 Ratio for Predicting Cardiovascular Risk in Pooled Analyses of the Incremental Decrease in Endpoints through Aggressive Lipid-Lowering (IDEAL) and Treating to New Targets (TNT) Trials 2006 ·Circulation ·John J.P. Kastelein,Ingar Holme,Philip J. Barter,Anders Olsson,Nilo B. Cater,David A. DeMicco,Michael Gaffney,Michael Szarek,John C. LaRosa,Terje R. Pedersen	2
17	Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trialbreakdown → 2003 ·The Lancet ·Hallvard Holdaas,Bengt Fellström,Alan G. Jardine,Ingar Holme,Gudrun Nyberg,Per Fauchald,Carola Grönhagen‐Riska,Sören Madsen,Hans‐Hellmut Neumayer,Edward Cole,Bart Maes,Patrice M. Ambühl,Anders Olsson,Anders Hartmann,D. Solbu,Terje R. Pedersen	660
18	Review of cholesterol-lowering therapy: Coronary angiographic and events trials 1996 ·The American Journal of Medicine ·David D. Waters,Terje R. Pedersen	17
19	Cholesterol Lowering and the Use of Healthcare Resources 1996 ·Circulation ·Terje R. Pedersen,John Kjekshus,Kåre Berg,Anders Olsson,Lars Wilhelmsen,Hans Wedel,Kalevi Pyörälà,Tatu A. Miettinen,Torben Haghfelt,Ole Færgeman,Guðmundur Þorgeirsson,Bengt Jönsson,J. Sanford Schwartz	137
20	Noninvasive evaluation of the effect of timolol on left ventricular performance after myocardial infarction and the consequence for prognosis 1987 ·Journal of the American College of Cardiology ·(unknown),Terje R. Pedersen,(unknown)	7

About Terje R. Pedersen

Terje R. Pedersen is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Economics and Econometrics, having authored 171 papers that have together received 25.2k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (123 papers), Health Systems, Economic Evaluations, Quality of Life (47 papers) and Pharmaceutical Economics and Policy (30 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (7.9k citations), Surgery (16.7k citations) and Cardiology and Cardiovascular Medicine (8.2k citations). Terje R. Pedersen has collaborated with scholars based in Norway, United States and United Kingdom. Frequent co-authors include Anders Olsson, John Kjekshus, Kalevi Pyörälà, Ole Færgeman, Ingar Holme, Robert P. Giugliano, Marc S. Sabatine, Anthony Keech, Guðmundur Þorgeirsson and Alberico L. Catapano. Their work appears in journals such as New England Journal of Medicine, The Lancet and JAMA.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact